跳至主要内容
临床试验/NCT01542541
NCT01542541已完成不适用

A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

Beth Israel Deaconess Medical Center1 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2011年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
68
试验地点
1
主要终点
SUVmax of FDG in Each Colonic Segment

研究概览

简要总结

Patients who undergo PET-CT scans to look for cancer are given an intravenous contrast (FDG) that is taken-up by active cells such as cancer cells. This contrast can then be seen in the body using the PET-CT scanner. However, cells in the colon also take up the FDG, and can produce "false positive" signals from the colon. Our hypothesis is that much of this signal comes from bacteria that are present in high concentrations in the colon. If this is the case, using an antibiotic to suppress the activity of bacteria may improve the ability of PET-CT to distinguish abnormal cells from normal cells in the colon.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients undergoing clinically-indicated PET-CT scan for non-GI lymphoma

排除标准

  • Patients with known Inflammatory Bowel Disease
  • Patients with known colon cancer

研究组 & 干预措施

Rifaximin

Experimental

干预措施: Rifaximin (Drug)

结局指标

主要结局

SUVmax of FDG in Each Colonic Segment

时间窗: Day 2

次要结局

  • SUVavg in Each Colonic Segment(Day 2)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Alan C. Moss

Assistant Professor of Medicine

Beth Israel Deaconess Medical Center

研究点 (1)

Loading locations...

相似试验